Every recall we track for Mylan Pharmaceuticals Inc. — 82 in all — plus the complaints and injury reports the public filed about them.
Mylan recalls 333mg Acamprosate Calcium tablets due to failed dissolution specifications. This may affect medication effectiveness. Contact Mylan for details.
Mylan recalls 500mg Mycophenolate Mofetil injections due to potential precipitate formation. Affected lots manufactured in India with specific NDC numbers and expiration dates.
Mylan recalls 40mg Isotretinoin capsules with failed dissolution specs. Check NDC 0378-6614-93, lots 3116110/311: 3x10-count packs expiring 07/2026.
Mylan recalls 5mg Prasugrel tablets with low dissolution risk. Check NDC 0378-5185-93 and lots 3211073-3211075 for affected products.
Mylan recalls insulin pens with missing labels to prevent medication errors. Affected pens have specific NDC numbers and were sold with expiration dates through August 2023.
Mylan recalls insulin glargine vials with missing labels to prevent medication errors. This insulin product (100 units/mL, 10mL vial) was manufactured with a missing label that could lead to incorrect dosing.
Mylan recalls Rifampin injections due to impurities found in stability testing. Affected lots expire Dec 2022 to Apr 2023. Stop using if you have these specific lots.
Mylan recalls Travoprost Ophthalmic Solution 0.004% 2.5mL bottles due to subpotent drug levels and impurities. This may affect prescription eye drops for glaucoma treatment.
Mylan recalls Proctofoam HC (hydrocortisone acetate 1% and pramoxine hydrochloride 1%) 10g aerosol containers due to cGMP deficiencies. Rx only products distributed by Meda Pharmaceuticals.
Mylan recalls Semglee (insulin glargine) prefilled pens with missing labels. Check your product's NDC 49502-0196-71 or 49502-0196-75 for affected units. No immediate action needed but label verification is critical for safe use.
